An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug

BMC Pulm Med. 2021 Mar 24;21(1):102. doi: 10.1186/s12890-021-01453-2.

Abstract

Background: Coronavirus Disease 2019 (COVID-19) is a pandemic affecting all countries in the world. Italy has been particularly afflicted by the health emergency, and since the peak phase has passed, major concern regarding medium to long term complications due to COVID-19 is arising. Little is known in literature regarding thromboembolic complications once healed after COVID-19.

Case presentation: A 51-year-old patient recovered from COVID-19 pneumonia complicated by pulmonary embolism (PE) came to the hospital for palpitations and chest pain. Although he was on treatment dose of direct oral anticoagulation (DOAC), massive recurrent PE was diagnosed.

Conclusion: In the early post COVID-19 era, the question remains regarding the efficacy of DOACs in COVID-19 patients.

Keywords: COVID-19; Case Report; Complications; Direct Oral Anticoagulation; Pulmonary Embolism.

Publication types

  • Case Reports

MeSH terms

  • Administration, Oral
  • Anticoagulants / administration & dosage*
  • Anticoagulants / therapeutic use
  • COVID-19 / complications*
  • Dabigatran / administration & dosage*
  • Dabigatran / therapeutic use
  • Drug Therapy, Combination
  • Heparin / administration & dosage*
  • Heparin / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Pulmonary Embolism / drug therapy
  • Pulmonary Embolism / prevention & control*
  • Pulmonary Embolism / virology*
  • Recurrence
  • Warfarin / administration & dosage*
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Warfarin
  • Heparin
  • Dabigatran